HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Estee Lauder

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder: Acquiring worldwide retail distribution rights to one of Les Laboratoires AEterna's cosmetic ingredients under an agreement announced by AEterna May 29. Under the deal, Lauder will "collaborate in the development of therapeutic products with AEterna with the aim of creating strategic alliances with pharmaceutical companies," the Quebec-based biotechnology firm AEterna said. The two-year agreement allows Lauder to incorporate the undisclosed ingredient in the company's Estee Lauder, Clinique, Prescriptives, Origins and Aramis brands but leaves the rights for future pharmaceutical and aesthetical applications with AEterna. The biotech firm anticipates that the sale of the ingredient could "substantially" augment its cosmetic division's turnover, generating about $10 mil. in revenues over the next five years. AEterna noted that the partnership allows the firm to "accelerate the creation of strategic alliances with pharmaceutical companies for the development of therapeutic dermatology products"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel